Anti-GPVI Antibody, clone 8E9, Capture Antibody

Evaluated by Western Blotting in recombinant human GPV1 glycoprotein.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected 0.1 µg of recombinant human GPV1 glycoprotein.

Anti-GPVI Antibody, clone 8E9, Capture Antibody is an antibody against GPVI for use in western blotting & ELISA.

ELISA Assay: A representative lot from an independent laboratory captured recombinant GPVI in a bead-based sandwich immunoassay (Bigalke, B., et al. (2011). Clin Chem. 57(6):898-904.). This antibody should be used in conjunction with Cat. No. MABT418, Anti-GPVI, clone 8A2, Detection Antibody, as an ELISA capture and detection antibody pair.

Glycoprotein VI (GPVI), or glycoprotein 6 (GP6), is a member of the immunoglobulin gene superfamily, closely related to Fc receptor gamma chain (FcRgamma) and natural killer receptors. GPVI is a collagen receptor involved in collagen-induced platelet adhesion and activation, and may contribute to arterial and venous thrombus formation. GPVI is a membrane glycoprotein that plays a crucial role in platelet procoagulant activity and subsequent thrombin and fibrin formation. GPVI is expressed in megakaryocytes and platelets. The signaling pathway of GPVI involves the FcRgamma, the Src kinases (likely Fyn/Lyn), the adapter protein LAT and leads to the activation of phospholipase C gamma2. It has been shown that bleeding disorders such as Bleeding Disorder Platelet-Type 11 (BDPLT11), a mild to moderate bleeding disorder caused by defective platelet activation and aggregation in response to collagen, is caused by defects in GPVI.

~50 kDa observed. The calculated molecular weight of this protein is 37 kDa However, a recombinant protein was observed at 50-55 kDa in Western Blotting.

Recombinant protein corresponding to human GPVI.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Replaces: MABT473

Format: Purified